The Supervisory Board of Medios AG has appointed Thomas Meier as a member of the Executive Board, effective February 1, 2026, designating him as the new Chief Executive Officer. He will succeed Matthias Gaertner, who will remain in office until December 31, 2025. The announcement signals a strategic leadership transition for the specialty pharmaceutical company.
Thomas Meier brings extensive experience from his role as CEO of Bachem Holding AG, a Swiss CDMO, since 2020. His background includes serving as Chief Operations Officer at Bachem and as Head of Manufacturing at Peninsula Laboratories in California. The Supervisory Board highlighted his track record of capital-efficient, profitable growth as key to Medios' next development phase.
Dr. Yann Samson, Chairman of the Supervisory Board, stated, "With Thomas Meier, we are gaining an internationally experienced leader with a strong track record of capital-efficient, profitable growth. We warmly welcome him and are convinced that his entrepreneurial spirit, expertise and leadership will contribute significantly to achieving our ambitious goals and sustainably increasing value for shareholders, partners, and customers." He also thanked Matthias Gaertner for his decade of service, noting his decisive influence on the company's growth.
Thomas Meier expressed enthusiasm for the role: "I am very much looking forward to the task of leading Medios into its next phase of development. Together with my colleagues on the Executive Board and the entire Medios team, I will continue to consistently develop the successful strategy and sustainably expand Medios’ position in the European Specialty Pharma market."
Medios AG is a leading provider of Specialty Pharma in Europe, with operations in Germany, the Netherlands, Belgium, and Spain. The company focuses on individualized medicine and innovative supply chain solutions. Its shares are listed on the Frankfurt Stock Exchange and included in the SDAX index. More information on their initiatives can be found at their individualized medicine page.
The leadership change comes as Medios prepares for key financial events, including its quarterly statement on November 11, 2025, and participation in the Berenberg European Conference on December 4, 2025. The transition is expected to maintain strategic continuity while leveraging Meier's operational expertise to drive growth.
